Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05309733 · ClinicalTrials.gov registry record

A Long-term Follow-up Study of Patients Who Received VOR33

A clinical trial, sponsored by Vor Biopharma.

Terminated
Registry status
10
Enrollment target

NCT05309733: Clinical Trial study, sponsored by Vor Biopharma.

NCT05309733 is a clinical trial that was terminated before completion, run by Vor Biopharma. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05309733 was terminated before completion, sponsored by Vor Biopharma.

TERMINATED
Registry status
10 participants
Enrollment target

Study Summary

VOR33 long-term follow-up (LTFU) study

Primary Outcome

Incidence of VOR33-related AEs/SAEs or deaths.

Interventions

  • GENETIC VOR33

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-04-15
Est. Completion 2025-05-28
Vor Biopharma

6 total trials

Why NCT05309733 stopped before completion

NCT05309733 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which VOR33 is the first listed.

NCT05309733 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05309733 about?

NCT05309733 is a clinical study titled "A Long-term Follow-up Study of Patients Who Received VOR33". VOR33 long-term follow-up (LTFU) study

What is the current status of trial NCT05309733?

This trial is currently terminated. The enrollment target is 10 participants. The study started on 2022-04-15. Estimated completion is 2025-05-28.

What interventions are being tested in trial NCT05309733?

The interventions under investigation include: VOR33 (GENETIC).

Who is sponsoring clinical trial NCT05309733?

This trial is sponsored by Vor Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05309733, the US trial registry maintained by the National Library of Medicine. NCT05309733 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.